OKOili Kaipiainen-Seppänen

Oili Kaipiainen-Seppänen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oili Kaipiainen-Seppänen has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study

    by T Sandström, O Kaipiainen-Seppänen, M Mali, M Kauppi, H Kautiainen, P Hannonen, T Yli-Kerttula, M Leirisalo-Repo, V Rantalaiho

    To evaluate whether rapid and sustained suppression of inflammation, using the NEO-RACo treatment, including prednisolone 7.5 mg/day for 2 years, in patients with early active rheumatoid arthritis (RA) can prevent the reduction of bone mineral density (BMD) in a 10 year follow-up. In the NEO-RACo study, 99 patients, aged 18-60 years, with early RA and without earlier use of disease-modifying anti-rheumatic drugs (DMARDs), were treated with a triple combination of conventional synthetic DMARDs and 7.5 mg prednisolone daily for 2 years and double blindly randomized to receive either placebo or infliximab infusions for the first 6 months. After 2 years, the therapies could be modified, always aiming for strict remission. All patients also received 1000 mg calcium and 800 IU vitamin D3 daily. BMD was measured by dual-energy X-ray absorptiometry at baseline, 2 years, 5 years, and 10 years. BMD Z-score ≤ -2.0 was considered to be below the expected value. At baseline, two patients (2%) had a Z-score ≤ -2.0, including one patient with osteoporosis. At the time of the last BMD measurement, five patients (5%) had a Z-score ≤ -2.0, and no new-onset osteoporosis cases occurred. No significant differences emerged between the randomization groups. Both randomization groups were treated early and aggressively, and the decrease in BMD was low throughout the 10 year follow-up. The use of infliximab during the first 6 months provided no extra benefit regarding bone loss.Trial Registration: http://www.clintrials.gov (NCT00908089).

  • Open Access

    Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes

    by Emil Hiitola, Juuso Korhonen, Heidi Kokkonen, Jukka Koskela, Matti Kankainen, Milla Alakuijala, Aoxing Liu, Sofie Lundgren, Paavo Häppölä, Henrikki Almusa, et al.

    Clonal hematopoiesis (CH) becomes more prevalent with aging and may influence inflammatory diseases by altering immune function. While CH of indeterminate potential (CHIP) promotes inflammation in nonmalignant conditions, its relationship with rheumatoid arthritis (RA) remains unknown. We analyzed CHIP mutations in RA using two population-level cohorts and patients with newly diagnosed RA. CHIP was associated with prevalent RA in 10,089 FINRISK study participants with whole-exome sequencing (OR, 2.06; P = 0.029) and in the FinnGen cohort ( n = 520,210; OR, 1.49; P < 0.001) using single-nucleotide polymorphism array–based CHIP annotation. In FinnGen, CHIP was also associated with inferior overall survival in participants with RA ( P = 0.013). In newly diagnosed RA ( n = 573), DNMT3A -mutated seropositive patients had increased inflammatory markers and disease activity compared with patients without CHIP. In contrast, TET2 mutations were enriched in seronegative RA ( P = 0.009). Our findings provide further evidence for the context-dependent association between CHIP and inflammation, with potential therapeutic implications.


  • Open Access

    Incidence of seropositive rheumatoid arthritis in population-based studies in Northern Savo, Finland, during 1980–2020

    by Pia Elfving, Aulikki Kononoff, Johanna Huhtakangas, Hannu Kautiainen, Elina Savolainen, Leena Arstila, Julia Barantseva, Tuomas Rannio, Helena Niinisalo, Antti Puolitaival, et al.

    The objective is to evaluate the incidence of seropositive rheumatoid arthritis (RA) over 40-year period in Northern Savo, Finland. Data on new seropositive RA patients according to the American College of Rheumatology (ACR) 1987 classification criteria were collected in 2020–2021. In 2020 data on tobacco exposure, patient-reported dental health and living in residences with fluoridated tap water were gathered. Incidence rates were estimated and age- and gender-adjusted to Northern Savo population. The results were compared with data acquired in studies from 1980, 1990, 2000, and 2010. In 2020, 46 seropositive RA patients (21 females and 25 males) were recorded. The crude incidence of seropositive RA fulfilling the ACR 87 criteria in 2020 was 22.3 (95% CI 16.3 to 29.8)/100 000 and age and gender-adjusted 22.3 (95% CI 15.9 to 28.8)/100 000. Tobacco exposure > 5 pack years occurred 18% of females and 56% of males. Only 16% of males were full dentate. A total of 242 incident seropositive RA (age ≥ 16 years, 55% females) were identified in all study years. No differences in the gender-specific incidence rates in each cohort or in incidence between the studies every 10 years were recorded. The incidence of seropositive RA decreased in the age group < 55 years, p = 0.003. There was no change in the incidence of seropositive RA between genders or the study years. A declining trend for occurrence of seropositive RA in the young and early middle-aged population may reflect change in risk factors.


  • Open Access

    Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

    by J. Hiltunen, P. Parmanne, T. Sokka, T. Lamberg, P. Isomäki, O. Kaipiainen-Seppänen, R. Peltomaa, T. Uutela, L. Pirilä, K. Taimen, et al.

    Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1–2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.


  • Antibodies to malondialdehyde-acetaldehyde modified low-density lipoprotein in patients with newly diagnosed inflammatory joint disease

    by A Kononoff, S Hörkkö, P Pussinen, H Kautiainen, P Elfving, E Savolainen, L Arstila, H Niinisalo, J Rutanen, O Marjoniemi, et al.

    Objective:To assess antibodies to malondialdehyde-acetaldehyde-modified low-density lipoprotein (MAA-LDL) in patients with newly diagnosed inflammatory joint disease. Method: Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and undifferentiated arthritis (UA), participating in the Northern Savo 2010 Study, were evaluated for metabolic syndrome (MetS), metabolic and inflammatory markers, antibodies to MAA-LDL,Aggregatibacter actinomycetemcomitans, andPorphyromonas gingivalis. Results: Among 135 newly diagnosed untreated patients, of whom 53 (39%) were diagnosed to have RA, 44 (33%) SpA, and 38 (28%) UA, 49%, 30%, and 47%, respectively, had MetS. After adjusting for age and gender, anti-MAA-LDL immunoglobulin (Ig)A (p = 0.009), IgG (p = 0.031), and IgM (p = 0.001) levels differed between the diagnostic categories, but not in patients with MetS present or absent. All antibody classes to MAA-LDL correlated with erythrocyte sedimentation rate (ESR), and IgA and IgG antibodies with high-sensitivity C-reactive protein (hs-CRP). IgA antibodies to MAA-LDL correlated with rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs), fasting plasma glucose, IgA antibodies toA. actinomycetemcomitans, and in IgA and IgG antibodies toP. gingivalis. Conclusion: Among various arthritis groups, antibodies to MAA-LDL were most common in RA. Antibodies to modified lipoproteins were associated with inflammation measured by ESR and hs-CRP. IgA antibodies to MAA-LDL correlated with age, antibodies to periodontal bacteria, RF, ACPA, and fasting glucose. Associations between antibodies to MAA-LDL and antibodies to periodontal bacteria, RA-associated antibodies, inflammatory parameters, and plasma glucose already reflect cardiovascular burden in inflammatory joint diseases at diagnosis.


  • Association of rheumatoid arthritis disease activity and antibodies to periodontal bacteria with serum lipoprotein profile in drug naive patients

    by Aulikki Kononoff, Pia Elfving, Pirkko Pussinen, Sohvi Hörkkö, Hannu Kautiainen, Leena Arstila, Leena Laasonen, Elina Savolainen, Helena Niinisalo, Jarno Rutanen, et al.

    Objective. We investigated lipid concentrations, particle sizes and antibodies binding to periodontal bacteria Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis, and to malondialdehyde-acetaldehyde modified low-density lipoprotein in immunoglobulin class A, G, and M among patients with newly diagnosed rheumatoid arthritis in a population-based cohort. Methods. Concentrations and sizes of lipoprotein particles analysed by proton nuclear magnetic resonance spectroscopy and antibody levels to malondialdehyde-acetaldehyde modified low-density lipoprotein were studied at baseline and after one-year of follow-up. Serum immunoglobulin A and G class antibodies to periodontal bacteria were determined at baseline. Results. Sixty-three patients were divided into tertiles according to disease activity by disease activity score with 28 joint count and erythrocyte sedimentation rate (4.7). Small low-density lipoprotein concentration was lowest in the tertile with the highest disease activity. In high-density lipoprotein, the concentrations of total, medium and small particles decreased with disease activity. The particle size in low-density lipoprotein associated with disease activity and the presence of antibodies to Porphyromonas gingivalis. Immunoglobulin G and M antibodies to malondialdehyde-acetaldehyde modified low-density lipoprotein correlated with disease activity. Inflammation associated changes faded by one year. Conclusion. Drug naive RA patients had proatherogenic changes in lipid profiles, but they were reversible, when inflammation diminished.


  • Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study

    by Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, et al.

    Objective.: To evaluate the development of radiological changes of the cervical spine in patients with rheumatoid arthritis (RA) in the NEO-RACo trial treated with an intensive, remission-targeted combination of conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and additional infliximab (IFX) or placebo (PLA) for the first 6 months.Methods.: Ninety-nine patients with early, DMARD-naive RA were treated with a triple combination of csDMARD and prednisolone, and randomized to double-blindly receive either IFX (FIN-RACo+IFX) or PLA (FIN-RACo+PLA) infusions during the first 6 months. After 2 years the treatment strategies became unrestricted, but the treatment goal was strict NEO-RACo remission. At the 10-year visit, radiographs of the cervical spine were taken of 85 patients (38 in the FIN-RACo+IFX group and 47 in the FIN-RACo+PLA group). The study was registered atClinicalTrials.gov(NCT 00908089).Results.: There were 4/85 patients (4.7%) with cervical spine involvement (CSI) by 10 years. Atlantoaxial subluxation was found in 2/85 patients (2.4%), both in the FIN-RACo+IFX group, and none in the FIN-RACo+PLA group. Atlantoaxial impaction was found in 1/85 patients (1.2%) in the FIN-RACo+IFX group. Subaxial subluxation was found in 1/85 patients (1.2%).Conclusion.: Early and intensive remission-targeted treatment has reduced the incidence of CSI and our results show that intensive treatment also prevents its development in the long run.


  • Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010

    by P. Elfving, O. Marjoniemi, H. Niinisalo, A. Kononoff, L. Arstila, E. Savolainen, J. Rutanen, O. Kaipiainen-Seppänen

    Objective of the study was to evaluate the annual incidence and distribution of autoimmune connective tissue diseases and vasculitides during 2010. All units practicing rheumatology in the Northern Savo area, Finland, participated in the study by collecting data on newly diagnosed adult patients with autoimmune connective tissue disease or vasculitis over 1-year period. Seventy-two cases with autoimmune connective tissue disease were identified. The annual incidence rates were as follows: systemic lupus erythematosus 3.4/100,000 (95 % CI 1.4–7.0), idiopathic inflammatory myopathies 1.9 (0.5–5.0), systemic sclerosis 4.4 (2.0–8.3), mixed connective tissue disease 1.0 (0.1–3.5), Sjögren’s syndrome 10.7 (6.7–16.1) and undifferentiated connective tissue disease 13.6 (9.0–19.6). The annual incidence rates among vasculitis category were as follows: antineutrophil cytoplasmic antibody-associated vasculitis 1.5/100,000 (95 % CI 0.3–4.3), central nervous system vasculitis 0.5 (0–2.7) and Henoch-Schönlein purpura 1.5 (0.3–4.3). The annual incidence of giant cell arteritis in the age group of 50 years or older was 7.5/100,000 (95 % CI 3.2–14.8). The longest delay from symptom onset to diagnosis occurred in systemic sclerosis. The incidences of autoimmune connective tissue diseases and vasculitides were comparable with those in published literature. The present study showed female predominance in all connective tissue diseases, excluding idiopathic inflammatory muscle diseases and mean age at onset of disease around 50 years of age. Despite improved diagnostic tools, diagnostic delay is long especially among patients with systemic sclerosis.


    • 20 October 2014
      • Vol. 32  (6) , 953-5

    Incidence of systemic lupus erythematosus in Finland, 2000-2007, a nationwide study.

    by Pia Elfving, Kari Puolakka, Hannu Kautiainen, Lauri J Virta, Timo Pohjolainen, Oili Kaipiainen-Seppänen

    To determine the age- and sex-specific incidence rates of systemic lupus erythematosus (SLE) in Finland. The incident cases were identified through diagnostic register searches for SLE on the nationwide database of the Social Insurance Institution. During the 8-year study period 599 incident cases occurred (518 females, 81 males). The mean annual incidence rate of SLE for adults was 1.69 per 100,000 (95% CI 1.56-1.84) and was highest among females aged 40-59 years. The gender incidence rate ratio was 6.43 (95% CI 5.06-8.26). The incidence for children was 0.39 (95% CI 0.27-0.55). The incidence of SLE was lower compared to the countries at the same latitudes. SLE in children remained a rarity.


    • 1 October 2006
      • Vol. 33  (11) , 2132-8

    Declining trend in the incidence of rheumatoid factor-positive rheumatoid arthritis in Finland 1980-2000.

    by Oili Kaipiainen-Seppanen, Hannu Kautiainen

    To investigate trends in the incidence of rheumatoid arthritis (RA) in Finland. We studied all the subjects entitled to receive drug reimbursement for chronic inflammatory joint diseases in 5/21 central hospital districts (population base about 1 million adults) in Finland during 2000. The incidence rates and the mean age at disease onset were compared with those from 1980, 1985, 1990, and 1995. A total of 714 subjects were entitled to drug reimbursement for chronic inflammatory joint disease that had started at the age of 16 or over. Of them, 321 satisfied the American College of Rheumatology classification criteria for RA, 198 had spondyloarthropathy, and 195 had undifferentiated oligo- or polyarthritis. The incidence of RA was 29.1/100,000 (95% CI 26.0-32.5); the figures for rheumatoid factor (RF)-positive RA and RF-negative RA were 18.2 (95% CI 15.8-21.0) and 10.8 (95% CI 9.0-12.9)/100,000, respectively. The incidence of RA was 36.9 (95% CI 32.1-42.2)/100,000 among women and 20.8 (95% CI 17.2-25.1)/100,000 among men. The age- and sex-adjusted incidence rate ratio declined from 1.00 in the referent year 1980 to 0.55 (95% CI 0.46-0.66) in 2000. A declining trend was evident for the incidence of RF-positive RA (p < or = 0.001). We verified the declining trend for the incidence of RF-positive RA in both sexes in Finland. Although the etiology of RA remains unknown, public health measures may reduce the risk of RA in the general population.